prognostic value

Prognostic Value of the PRAME Gene Expression in T-Cell Lymphoproliferative Disorders

LYMPHOID TUMORS , ,

EA Penskaya1, VA Misyurin2, AE Misyurina1, SK Kravchenko1, LG Gorenkova1, LV Plastinina1, VV Tikhonova2, YuP Finashutina2, NA Lyzhko2, NN Kasatkina2, LA Kesaeva2, ON Solopova2, AV Misyurin2

1 National Medical Hematology Research Center, 4a Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

2 NN Blokhin National Medical Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

For correspondence: Vsevolod Andreevich Misyurin, PhD in Biology, 24 Kashirskoye sh., Moscow, Russian Federation, 115478; Tel.: +7(985)436-30-19; e-mail: vsevolod.misyurin@gmail.com

For citation: Penskaya EA, Misyurin VA, Misyurina AE, et al. Prognostic Value of the PRAME Gene Expression in T-Cell Lymphoproliferative Disorders. Clinical oncohematology. 2019;12(1):73–78.

DOI: 10.21320/2500-2139-2019-12-1-73-78

ABSTRACT

Background. T-cell lymphomas (T-CL) represent a heterogeneous group of malignant lymphoproliferative disorders characterized by unfavorable prognosis. The cancer-testis PRAME gene is notable for its spontaneous expression in transformed cells as observed in solid tumors, B-cell lymphoproliferative and chronic myeloproliferative diseases. Activity and clinical significance of PRAME in T-CL was not studied before, which determines the relevance and provides ground for the present trial.

Aim. To assess the clinical significance of the PRAME gene expression in T-CL.

Materials & Methods. PRAME gene expression level was measured in samples of lymph nodes, blood, and bone marrow from 35 T-CL patients. Among them 3 patients received allogeneic hematopoietic stem cell transplantation, and 6 patients received autologous hematopoietic stem cell transplantation. A correlation was established between the PRAME expression in bone marrow and peripheral blood with morphological markers of disseminated disease with bone marrow lesions and leukemic blood. PRAME expression level was correlated with survival parameters and tumor proliferative activity (Ki-67).

Results. PRAME activity was observed in 21 (60 %) patients. PRAME hyperexpression is associated with advanced stages of disease (p = 0.0734), bone marrow lesions (p = 0.0289), leukemic blood (p = 0.0187), worsening of the overall survival (OS) (p = 0.0787) and event-free survival (EFS) (p = 0.7185), also after hematopoietic stem cell transplantation (p = 0.2661 for OS and p = 0.0452 for EFS), and with a high Ki-67 expression level (p = 0.0155).

Conclusion. PRAME expression in T-CL is often observed and related with unfavorable clinical prognosis.

Keywords: PRAME, T-cell lymphoproliferative disorders, prognostic value.

Received: April 24, 2018

Accepted: December 27, 2018

Read in PDF 

REFERENCES

  1. Greer JP, Kinney MC, Loughran TP Jr. T cell and NK cell lymphoproliferative disorders. Hematology. 2001;2001(1):259–81. doi: 10.1182/asheducation-2001.1.259.

  2. Bo J, Zhao Y, Zhang S, et al. Long-term outcomes of peripheral blood stem cell transplantation for 38 patients with peripheral T-cell lymphoma. J Cancer Res Ther. 2016;12(3):1189–97. doi: 10.4103/0973-1482.189235.

  3. Мангасарова Я.К., Магомедова А.У., Кравченко С.К. и др. Восьмилетний опыт лечения агрессивных В-крупноклеточных лимфом средостения. Терапевтический архив. 2013;85(7):50–6.

    [Mangasarova YaK, Magomedova AU, Kravchenko SK, et al. Eight-year experience in treating aggressive mediastinal large B-cell lymphomas. Terapevticheskii arkhiv. 2013;85(7):50–6. (In Russ)]

  4. Turgeon ML. Clinical hematology: theory and procedures. Hagerstown, MD: Lippincott Williams & Wilkins; 2005. pp. 283.

  5. Горенкова Л.Г., Пенская Е.А., Кравченко С.К. и др. Лечение резистентных форм грибовидного микоза и синдрома Сезари. Клиническая онкогематология. 2017;10(3):366–71. doi: 10.21320/2500-2139-2017-10-3-366-371.

    [Gorenkova LG, Penskaya EA, Kravchenko SK, et al. Treatment of Drug-Resistant Mycosis Fungoides and Sezary Syndrome. Clinical oncohematology. 2017;10(3):366–71. doi: 10.21320/2500-2139-2017-10-3-366-371. (In Russ)]

  6. Мисюрин В.А. Клиническое значение экспрессии гена PRAME при онкогематологических заболеваниях. Клиническая онкогематология. 2018;11(1):26–33. doi: 10.21320/2500-2139-2018-11-1-26-33.

    [Misyurin VA. Clinical Significance of the PRAME Gene Expression in Oncohematological Diseases. Clinical oncohematology. 2018;11(1):26–33. doi: 10.21320/2500-2139-2018-11-1-26-33. (In Russ)]

  7. Мисюрин В.А. Прогностическое значение экспрессии гена PRAME при солидных опухолях. Иммунология. 2018;39(1):67–73. doi: 10.18821/0206-4952-2018-39-1-67-73.

    [Misyurin VA. Prognostic value of prame’s gene expression in solid tumors. Immunology. 2018;39(1):67–73. doi: 10.18821/0206-4952-2018-39-1-67-73. (In Russ)]

  8. Мисюрин В.А., Лукина А.Е., Мисюрин А.В. и др. Особенности соотношения уровней экспрессии генов PRAME и PML/RARα в дебюте острого промиелоцитарного лейкоза. Российский биотерапевтический журнал. 2014;13(1):9–16.

    [Misyurin VA, Lukina AE, Misyurin AV, et al. A ratio between gene expression levels of PRAME and PML/RARα at the onset of acute promyelocytic leukemia. Rossiiskii bioterapevticheskii zhurnal. 2014;13(1):9–16. (In Russ)]

  9. Santamaria C, Chillon MC, Garcia-Sanz R, et al. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. Haematologica. 2008;93(12):1797–805. doi: 10.3324/haematol.13214.

  10. Doolan P, Clynes M, Kennedy S, et al. Prevalence and prognostic and predictive relevance of PRAME in breast cancer. Breast Cancer Res Treat. 2008;109(2):359–65. doi: 10.1007/s10549-007-9643-3.

  11. Nalini V, Segu R, Deepa PR, et al. Molecular insights on post-chemotherapy retinoblastoma by microarray gene expression analysis. Bioinform Biol Insights. 2013;7:289–306. doi: 10.4137/BBI.S12494.

  12. Mitsuhashi K, Masuda A, Wang YH, et al. Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy. Int J Hematol. 2014;100(1):88–95. doi: 10.1007/s12185-014-1593-z.

  13. Мисюрин В.А., Мисюрин А.В., Кесаева Л.А. и др. Новые маркеры прогрессирования хронического миелолейкоза. Клиническая онкогематология. 2014;7(2):206–12.

    [Misyurin VA, Misyurin AV, Kesaeva LA, et al. New molecular markers of CML progression. Klinicheskaya onkogematologiya. 2014;7(2):206–12. (In Russ)]

  14. Matsushita M, Ikeda H, Kizaki M, et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol. 2001;112(4):916–26. doi: 10.1046/j.1365-2141.2001.02670.x.

  15. Liggins AP, Lim SH, Soilleux EJ, et al. A panel of cancer-testis genes exhibiting broad spectrum expression in haematological malignancies. Cancer Immun. 2010;10:8.

  16. Wadelin FR, Fulton J, Collins HM, et al. PRAME is a golgi-targeted protein that associates with the Elongin BC complex and is upregulated by interferon-gamma and bacterial PAMPs. PLoS One. 2013;8(2):e58052. doi: 10.1371/journal.pone.0058052.

  17. Мисюрин В.А. Теория и практика иммунотерапии, направленной против антигена PRAME. Клиническая онкогематология. 2018;11(2):138–49. doi: 10.21320/2500-2139-2018-11-2-138-149. [Misyurin VA. Theory and practice of immunotherapy directed against the PRAME antigen. Clinical oncohematology. 2018;11(2):138–49. doi: 10.21320/2500-2139-2018-11-2-138-149. (In Russ)]

  18. Финашутина Ю.П., Мисюрин А.В., Ахлынина Т.В. и др. Получение рекомбинантного раково-тестикулярного белка PRAME и моноклональных антител к нему. Российский биотерапевтический журнал. 2015;4(3):29–36.

    [Finashutina YuP, Misyurin AV, Akhlynina TV, et al. Production of purified human recombinant antigen PRAME and specific monoclonal antibodies. Rossiiskii bioterapevticheskii zhurnal. 2015;(4)3:29–36. (In Russ)]

  19. Лыжко Н.А., Мисюрин В.А., Финашутина Ю.П. и др. Проявление цитостатического эффекта моноклональных антител к белку PRAME. Российский биотерапевтический журнал. 2016;15(4):53–8. doi: 10.17650/1726-9784-2016-15-4-53-58.

    [Lyzhko NA, Misyurin VA, Finashutina YuP, et al. Development of cytostatic effect of monoclonal antibodies to the protein PRAME. Rossiiskii bioterapevticheskii zhurnal. 2016;15(4):53–58. doi: 10.17650/1726-9784-2016-15-4-53-58. (In Russ)]

  20. Epping MT, Wang L, Plumb JA, et al. A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2007;104(45):17777–82. doi: 10.1073/pnas.0702518104.

  21. Qin Y, Lu J, Bao L, et al. Bortezomib improves progression-free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma. Chinese Med J. 2014;127(9):1666–71.

  22. Гапонова Т.В., Менделеева Л.П., Мисюрин А.В. и др. Экспрессия опухолеассоциированных генов PRAME, WT1 и XIAP у больных множественной миеломой. Онкогематология. 2009;2:52–7.

    [Gaponova TV, Mendeleeva LP, Misyurin AV, et al. Expression of PRAME, WT1 and XIAP tumor-associated genes in patients with multiple myeloma. Onkogematologiya. 2009;2:52–7. (In Russ)]

  23. Вотякова О.М. Новые возможности лечения рецидивов и рефрактерной множественной миеломы (обзор литературы). Клиническая онкогематология. 2017;10(4):425–34. doi: 10.21320/2500-2139-2017-10-4-425-434.

    [Votyakova OM. New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review. Clinical oncohematology. 2017;10(4):425–34. doi: 10.21320/2500-2139-2017-10-4-425-434. (In Russ)]

  24. Costessi A, Mahrour N, Tijchon E, et al. The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters. EMBO J. 2011;30(18):3786–98. doi: 10.1038/emboj.2011.262.